Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q1 FY26 Earnings Presentation
16 slides from Ngl Fine-chem's earnings presentation, Aug 7, 2025
Slide 1: Cover letter to stock exchanges: Investor Presentation for quarter ended June 30, 2025
O NGL Fine-Chem Limited Regd. Office 301, E - Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India. Tel.: (+91 22) 40842222, Fax: (+91 22) 2610 8030, Email: info@naffinechem.com CIN’ L24110MH1981PLC025884, Website www.ngffinechem.com August 7, 2025 To, Listing Department, Listing
Slide 2: NGL Fine-Chem Limited
ONGL Fine-Chem Ltd NGL Fine-Chem NNNNNNNNNNNNNNNNNNNN Limited
Slide 3: Disclaimer
Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be d
Slide 4: Inside This Presentation
Inside This Presentation Pg. No. Pg. No. 04 11 QIFY26 Overview, Highlights Key Strengths and Strategy ‘ Pg. No. » 16 Historical Financial Performance
Slide 5: QTFY26 Highlights
01 QTFY26 Highlights 05 MANAGEMENT COMMENTARY 06 QUARTERLY OPERATIONAL METRICS 07 SUMMARY OF PROFIT AND LOSS STATEMENT
Slide 6: Management Commentary
MANAGEMENT COMMENTARY Dear Shareholders, “The operating environment remained On the investment front, we continue to make challenging during QIT1FY26, impacted by a steady progress on our CAPEX initiatives. Owing combination of industry headwinds and to certain executional delays, the completion mac
Slide 7: Quarterly Operational Metrics
Quarterly Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION ANIMAL API 90% 90% 92% TOP 3 PRODUCTS 32% 33% 30% HUMAN API 5% 7% eE TOP 5 PRODUCTS 47% 50% 2% INTERMEDIATES 3% 1% 3% TOP 10 PRODUCTS 71% 72% 63% FORMULATIONS 2% 2% 1% GEOGRAPHIC MIX CUSTOMER CONCENTRATION Asla 35% 37% 22 TOP
Slide 8: Summary of Profit and Loss Statement
Summary of Profit and Loss Statement T IN CRORES G REVENUE FROM OPERATIONS ) N 90.75 94.97 T O 104.19 9.70% )14.80% OTHER INCOME 5.88 -0.97 6.35 757.98% 7.97% TOTAL INCOME 96.64 94.01 110.54 17.59% 14.38% TOTAL OPERATING EXPENSES 8140 88.65 93.21 5.14% 14.51% EBITDA 9.35 6.32 10.97 73.64% 17.36% EBI
Slide 9: Overview, Strengths and Strategy
02 Overview, Strengths and Strategy 09 LEADING ANIMAL HEALTH COMPANY 10 LEADERSHIP IN VETERINARY APl SEGMENT 11 STATE-OF-THE-ART MANUFACTURING CAPABILITIES 12 STRATEGY FOR NEXT LEG OF GROWTH
Slide 10: Leading Animal Health Company
~ Leading Animal Health Companyj \‘1 w5 ) k4 COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS * 35 APIs (33 Veterinary » Market leadership in + 3 state of the art « Strong presence ¢ ~404 customers
Slide 11: Leadership in Veterinary API Segment
Leadership in Veterinary APl Segmen o) N REVENUE FROM VETERINARY CUSTOMER & PRODUCT Strong controls of processes with API SEGMENT 1 27 CONCENTRATION 95% in-house manufacturing and (X IN CRORES) CAGRD (OF SALES FY25) backward integrated facilities leading to cost competitiveness FY25 327 FY24 [ ] 300
Slide 12: State-of-the-art Manufacturing Capabilities
State-of-the-art Manufacturing Capabiliti9 HIGHLIGHTS 3 manufacturing facilities 19'000|,nz 1 68 K 253 K located at Tarapur & Navi . AREA OF GLASS-LINED STAINLESS STEEL Mumbai, Maharashtra, MANUFACTURING REACTORS REACTORS designed to meet the FACILITIES requirements of regulatory agencies and are ca
Slide 13: Strategy for next leg of growth
- " Strategy for next leg of grow Jel (BROWNFIELD EXPANSION) N d;bA + Completed expansion in ONGOING INITIATIVES subsidiary Macrotech TO INCREASE « Additional capacities of CAPACITIES TO MEET intermediates GROWING DEMAND « Commercial production started ( GREENFIELD EXPANSION AT TARAPUR ) « Capacity
Slide 14: Historical Financial Performance
03 Historical Financial Performance 14 ROBUST FINANCIAL PERFORMANCE
Slide 15: Robust Financial Performance
™ Robust Financial Performan? REVENUE EBITDA PAT (% IN CRORES) (% IN CRORES) (% IN CRORES) Fr2s I 368 Fr2s N 34 Fr24 S 21 FY24 | 1339 Fye4a 153 Fyea M Fye3s 1278 Fv23 [ 134 Fve3 121 Fyea 1318 Fyea 68 Fr22 | ] 50 Fy21 1258 FY21 | ] 80 Fy21 | ] 57 GROSS MARGIN EBITDA MARGIN PAT MARGIN (IN %) (IN %) (I
Slide 16: Thank You
FOR ANY FURTHER INFORMATION, PLEASE CONTACT Pallavi Pednekar Abhishek Mehra Thank You NGL FINE-CHEM TIL ADVISORS PRIVATE LIMITED LIMITED cs@nglfinechem.com abhishek@theinvestmentlab.in +91 22 40842222 +91 95588 14500 ONGL Fine-Chem Ltd Corporate Office 301, E-square, Subhash Road, Vile Parle (East),